APA (7th ed.) Citation

Beran, D., Abidha, C. A., Adler, A., de Beaufort, C., Lepeska, M., Levitt, N., . . . Gale, E. A. (2023). Teplizumab approval for type 1 diabetes in the USA. The lancet. Diabetes & Endocrinology, 11(2), . https://doi.org/10.1016/S2213-8587(22)00384-9

Chicago Style (17th ed.) Citation

Beran, David, Carol Akinyi Abidha, Amanda Adler, Carine de Beaufort, Molly Lepeska, Naomi Levitt, Elizabeth Pfiester, Jessica H. Zafra-Tanaka, and Edwin AM Gale. "Teplizumab Approval for Type 1 Diabetes in the USA." The Lancet. Diabetes & Endocrinology 11, no. 2 (2023). https://doi.org/10.1016/S2213-8587(22)00384-9.

MLA (9th ed.) Citation

Beran, David, et al. "Teplizumab Approval for Type 1 Diabetes in the USA." The Lancet. Diabetes & Endocrinology, vol. 11, no. 2, 2023, https://doi.org/10.1016/S2213-8587(22)00384-9.